Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
In the latest session, Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) closed at $29.52 up 0.54% from its previous closing price of $29.36. In other words, the price has increased by $0.54 from its previous closing price. On the day, 1.17 million shares were traded. RARE stock price reached its highest trading level at $29.62 during the session, while it also had its lowest trading level at $28.87.
Ratios:
For a deeper understanding of Ultragenyx Pharmaceutical Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.30 and its Current Ratio is at 2.45. In the meantime, Its Debt-to-Equity ratio is 5.84 whereas as Long-Term Debt/Eq ratio is at 5.34.
Goldman Upgraded its Neutral to Buy on June 06, 2024, whereas the target price for the stock was revised from $56 to $67.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jun 20 ’25 when Sanders Corazon (Corsee) D. sold 2,405 shares for $37.39 per share. The transaction valued at 89,923 led to the insider holds 15,344 shares of the business.
CORAZON D. SANDERS bought 2,405 shares of RARE for $89,923 on Jun 20 ’25. On May 05 ’25, another insider, Crombez Eric, who serves as the EVP and Chief Medical Officer of the company, sold 520 shares for $39.24 each. As a result, the insider received 20,405 and left with 71,530 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RARE now has a Market Capitalization of 2844889600 and an Enterprise Value of 3242105856. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.66 while its Price-to-Book (P/B) ratio in mrq is 18.77. Its current Enterprise Value per Revenue stands at 5.314 whereas that against EBITDA is -6.903.
Stock Price History:
The Beta on a monthly basis for RARE is 0.20, which has changed by -0.47982377 over the last 52 weeks, in comparison to a change of 0.13054323 over the same period for the S&P500. Over the past 52 weeks, RARE has reached a high of $60.37, while it has fallen to a 52-week low of $25.81. The 50-Day Moving Average of the stock is -7.37%, while the 200-Day Moving Average is calculated to be -23.95%.
Shares Statistics:
For the past three months, RARE has traded an average of 1.92M shares per day and 1405670 over the past ten days. A total of 96.18M shares are outstanding, with a floating share count of 89.64M. Insiders hold about 6.99% of the company’s shares, while institutions hold 98.06% stake in the company. Shares short for RARE as of 1753920000 were 7638230 with a Short Ratio of 3.98, compared to 1751241600 on 6820252. Therefore, it implies a Short% of Shares Outstanding of 7638230 and a Short% of Float of 8.2100004.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
